{ "reviewed_on": "2026-09-08", "scope": "Selected China-origin ADC programs, including overseas subsidiaries of Chinese groups; US licensing partners since 2023; current Phase 2/3 anywhere globally. Not exhaustive. Announcement dates and license months are distinct from signing dates.", "assets": [ { "asset": "BL-B01D1 / izalontamab brengitecan", "target": "EGFR / HER3", "developer_and_licensor": "SystImmune (US); parent Sichuan Biokin (China)", "licensee": "Bristol Myers Squibb", "announcement_date": "2023-12-11", "phase_at_announcement": "Global Phase 1 disclosed; highest China phase at signing not established here", "reviewed_phase": "Phase 3 in China: TNBC, ESCC and nasopharyngeal carcinoma", "decision": "Retained", "territory": "US co-development/co-commercialization; BMS exclusive rest-of-world rights outside mainland China", "agreement_source": "https://investors.bms.com/iframes/press-releases/press-release-details/2023/SystImmune-and-Bristol-Myers-Squibb-Announce-a-Global-Strategic-Collaboration-Agreement-for-the-Development-and-Commercialization-of-BL-B01D1/default.aspx", "phase_source": "https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx", "reviewed_on": "2026-09-08", "contracting_licensor": "SystImmune (United States)", "originating_group": "Sichuan Biokin (China)", "date_basis": "Announcement date; not signing date", "origin_source": "https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx" }, { "asset": "CRB-701 / SYS6002", "target": "Nectin-4", "developer_and_licensor": "CSPC Megalith (China); parent CSPC Pharmaceutical Group", "licensee": "Corbus Pharmaceuticals", "announcement_date": "2023-02 (license month reported in 10-K)", "phase_at_announcement": "China Phase 1 reported in 2023; exact signing-day phase not independently established", "reviewed_phase": "China: Phase 3 cervical cancer, Phase 2 mUC; US/Europe Phase 2 and 3 marked pending on pipeline", "decision": "Retained", "territory": "US, Canada, EU/EFTA, UK and Australia", "agreement_source": "https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0000950170-24-030133/crbp-20231231.htm", "phase_source": "https://www.corbuspharma.com/our-pipeline", "reviewed_on": "2026-09-08", "contracting_licensor": "CSPC Megalith (China)", "originating_group": "CSPC Pharmaceutical Group (China)", "date_basis": "License month reported in annual filing", "origin_source": "https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0000950170-24-030133/crbp-20231231.htm" }, { "asset": "SHR-4849 / IDE849", "target": "DLL3", "developer_and_licensor": "Hengrui Pharma", "licensee": "IDEAYA Biosciences", "announcement_date": "2024-12-29", "phase_at_announcement": "Phase 1", "reviewed_phase": "Phase 2 shown for monotherapy in a Phase 1/2 program; combination arm Phase 1", "decision": "Retained", "territory": "Outside Greater China", "agreement_source": "https://media.ideayabio.com/2024-12-29-IDEAYA-Biosciences-Enters-Exclusive-License-with-Hengrui-Pharma-for-SHR-4849%2C-a-Novel-Phase-1-DLL3-Topo-I-Payload-ADC-Targeting-SCLC-and-NET-Solid-Tumors", "phase_source": "https://www.ideayabio.com/pipeline", "reviewed_on": "2026-09-08", "contracting_licensor": "Hengrui Pharma (China)", "originating_group": "Hengrui Pharma (China)", "date_basis": "Announcement date; not signing date", "origin_source": "https://media.ideayabio.com/2024-12-29-IDEAYA-Biosciences-Enters-Exclusive-License-with-Hengrui-Pharma-for-SHR-4849%2C-a-Novel-Phase-1-DLL3-Topo-I-Payload-ADC-Targeting-SCLC-and-NET-Solid-Tumors" }, { "asset": "JSKN016", "target": "TROP2 / HER3", "developer_and_licensor": "Jiangsu Alphamab", "licensee": "Pathos AI", "announcement_date": "2026-08-03", "phase_at_announcement": "Phase 3 TNBC; earlier-phase studies also ongoing", "reviewed_phase": "Phase 3 TNBC reported ongoing in August 2026", "decision": "Retained", "territory": "Outside mainland China, Hong Kong, Macau and Taiwan", "agreement_source": "https://www.pathos.com/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc", "phase_source": "https://www.pathos.com/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc", "reviewed_on": "2026-09-08", "contracting_licensor": "Jiangsu Alphamab (China)", "originating_group": "Alphamab Oncology (Jiangsu operating subsidiary, China)", "date_basis": "Announcement date; not signing date", "origin_source": "https://www.pathos.com/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc" }, { "asset": "MRG007 / ARR-217", "target": "CDH17", "developer_and_licensor": "Lepu Biopharma", "licensee": "ArriVent BioPharma", "announcement_date": "2025-01-21", "phase_at_announcement": "Preclinical", "reviewed_phase": "Phase 1b dose optimization as of 12 August 2026", "decision": "Excluded: Phase 2/3 not supported", "territory": "Outside Greater China", "agreement_source": "https://ir.arrivent.com/node/7121/pdf", "phase_source": "https://ir.arrivent.com/news-releases/news-release-details/arrivent-biopharma-reports-second-quarter-2026-financial-results", "reviewed_on": "2026-09-08", "contracting_licensor": "Lepu Biopharma (China)", "originating_group": "Lepu Biopharma (China)", "date_basis": "Announcement date; not signing date", "origin_source": "https://ir.arrivent.com/node/7121/pdf" } ] }